News and Stories

 2/6/2024

 12/4/2023
  • Ruli co-organized CSHA-Frontiers in Single Cell Genomics meeting. 

Conference Link: https://csh-asia.org/?list/34 

 10/1/2023
  • Dr. Minhua Wang joined the lab. Welcome!

 9/5/2023
  • Dr. Yueying He joined the lab.  Welcome!

 6/27/2023
  • scNanoGPS is accepted for publication in Nature Communications
  • Congratulations to Drs. Cheng-Kai Shiau, Lina Lu, Rachel Kieser and all other co-authors!

Single-cell nanopore sequencing of full-length mRNAs transforms single-cell multi-omics studies. However, challenges include high sequencing errors and dependence on short-reads and/or barcode whitelists. To address these, we develop scNanoGPS to calculate same-cell genotypes (mutations) and phenotypes (gene/isoform expressions) without short-read nor whitelist guidance. We apply scNanoGPS onto 23,587 long-read transcriptomes from 4 tumors and 2 cell-lines. Standalone, scNanoGPS deconvolutes error-prone long-reads into single-cells and single-molecules, and simultaneously accesses both phenotypes and genotypes of individual cells. Our analyses reveal that tumor and stroma/immune cells express distinct combination of isoforms (DCIs). In a kidney tumor, we identify 924 DCI genes involved in cell-type-specific functions such as PDE10A in tumor cells and CCL3 in lymphocytes. Moreover, transcriptome-wide mutation analyses identify many cell-type-specific mutations including VEGFA mutations in tumor cells and HLA-A mutations in immune cells, highlighting critical roles of different mutant populations in tumors. Together, scNanoGPS facilitates applications of single-cell long-read sequencing technologies.

Paper link: https://www.nature.com/articles/s41467-023-39813-7

News report: https://news.feinberg.northwestern.edu/2023/08/15/novel-sequencing-tool-accelerates-analysis-of-tumor-cells/

 6/29/2023
  • Ruli broadcasted single cell long read RNA sequenicing in ONT webinar series.

 4/14/2023
  • Ruli presented scNanoGPS at AACR, ONT Spotlight Theater.

 4/11/2023
  • Anaplastic transformation story is accepted for publication in JCI
  • News story - Understanding how aggressive thyroid cancer evolves
  • Congratulations to Dr. Lina Lu and all co-authors!

The deadliest anaplastic thyroid cancer (ATC) often transforms from indolent differentiated thyroid cancer (DTC); however, the complex intratumor transformation process is poorly understood. We investigated an anaplastic transformation model by dissecting both cell lineage and cell fate transitions using single-cell transcriptomic and genetic alteration data from patients with different subtypes of thyroid cancer. The resulting spectrum of ATC transformation included stress-responsive DTC cells, inflammatory ATC cells (iATCs), and mitotic-defective ATC cells and extended all the way to mesenchymal ATC cells (mATCs). Furthermore, our analysis identified 2 important milestones: (a) a diploid stage, in which iATC cells were diploids with inflammatory phenotypes and (b) an aneuploid stage, in which mATCs gained aneuploid genomes and mesenchymal phenotypes, producing excessive amounts of collagen and collagen-interacting receptors. In parallel, cancer-associated fibroblasts showed strong interactions among mesenchymal cell types, macrophages shifted from M1 to M2 states, and T cells reprogrammed from cytotoxic to exhausted states, highlighting new therapeutic opportunities for the treatment of ATC.

Paper link: https://www.jci.org/articles/view/169653

News report: https://news.feinberg.northwestern.edu/2023/05/19/understanding-how-aggressive-thyroid-cancer-evolves/

 4/3/2023
  • Dr. Lina Lu received the Katten Muchin Rosenman Travel Scholarship. Congratulations!

 

 4/3/2023
  • Dr. Cheng-Kai Shiau received the Katten Muchin Rosenman Travel Scholarship. Well-derserved!

 12/10/2020
  • CopyKAT is accepted for publication in Nature Biotechnology
  • News story - New high-throughput analytic enables differentiation of tumor cells within its microenvironment


Single-cell transcriptomic analysis is widely used to study human tumors. However, it remains challenging to distinguish normal cell types in the tumor microenvironment from malignant cells and to resolve clonal substructure within the tumor. To address these challenges, we developed an integrative Bayesian segmentation approach called copy number karyotyping of aneuploid tumors (CopyKAT) to estimate genomic copy number profiles at an average genomic resolution of 5 Mb from read depth in high-throughput single-cell RNA sequencing (scRNA-seq) data. We applied CopyKAT to analyze 46,501 single cells from 21 tumors, including triple-negative breast cancer, pancreatic ductal adenocarcinoma, anaplastic thyroid cancer, invasive ductal carcinoma and glioblastoma, to accurately (98%) distinguish cancer cells from normal cell types. In three breast tumors, CopyKAT resolved clonal subpopulations that differed in the expression of cancer genes, such as KRAS, and signatures, including epithelial-to-mesenchymal transition, DNA repair, apoptosis and hypoxia. These data show that CopyKAT can aid in the analysis of scRNA-seq data in a variety of solid human tumors.

Paper Link: https://www.nature.com/articles/s41587-020-00795-2

News Report: https://read.houstonmethodist.org/new-high-throughput-analytic-enables-differentiation-of-tumor-cells-wi 

Follow on